Yüksel Ürün: PSMA-PET by PROMISE effective in high/low-risk stratification in prostate cancer
Yüksel Ürün shared on X about a recent paper titled “Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study” published on The Lancet Oncology.
Authors: Madeleine J. Karpinski, Johannes Hüsing, Kevin Claassen, Lennart Möller, Hiltraud Kajüter, Florian Oesterling, Viktor Grünwald, Lale Umutlu, Jens Kleesiek, Tugce Telli, Anja Merkel-Jens, Anika Hüsing, Claudia Kesch, Ken Herrmann, Matthias Eiber, Sebastian Hoberück, Philipp T. Meyer, Felix Kind, Kambiz Rahbar, Michael Schäfers, Andreas Stang, Boris A. Hadaschik, Wolfgang P. Fendler.
“PSMA-PET by PROMISE (PPP) outperformed established risk scores, proving effective in high/low-risk stratification in prostate cancer. Ongoing validation continues.”
Source: Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023